Welcome to the
NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Darin Okuda, MD, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more.
Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.
Episode Breakdown:
1:20 – Overview of ARISE and conduct of study
4:20 – Potential subgroup responders to dimethyl fumarate
8:10 – Efforts to improve the detection of radiologically isolated syndrome
10:05 – Neurology News Minute
11:55 – Next steps of research following ARISE
16:50 – Closing thoughts on significance of the study
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Thanks for listening to the
NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit
neurologylive.com.
REFERENCE
Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl fumarate delays multiple sclerosis radiologically isolated syndrome.
Ann Neurol. 2023;93(3):604-614. doi:10.1002/ana.26555
